古塞奇尤单抗(Guselkumab) - 药物靶点：IL-23p19_在研适应症：活动性中度克罗恩病，活动性重度克罗恩病，活动性中度溃疡性结肠炎_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Guselkumab (Genetical Recombination)、Guselkumab (genetical recombination) (JAN)、Guselkumab (USAN)

+ [8]

靶点

IL-23p19

作用方式

抑制剂

作用机制

IL-23p19抑制剂(白细胞介素-23亚单位p19抑制剂)

治疗领域

免疫系统疾病感染消化系统疾病+ [5]

在研适应症

活动性中度克罗恩病活动性重度克罗恩病活动性中度溃疡性结肠炎+ [23]

非在研适应症

腺瘤性结肠息肉病乳糜泻泛发性脓疱型银屑病+ [5]

原研机构

Janssen Global Services LLC

在研机构

Janssen Pharmaceutica NVJanssen-Cilag International NV

西安杨森制药有限公司

+ [10]

非在研机构-

权益机构

Janssen Pharmaceuticals, Inc.

Celsius Therapeutics, Inc.

MorphoSys AG

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2017-07-13),

斑块状银屑病

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)、突破性疗法 (中国)、临床急需境外新药 (中国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

Sequence Code 9493545H

来源: *****

Sequence Code 9493571L

来源: *****

关联

95

项与古塞奇尤单抗相关的临床试验

NCT06916390

/ Not yet recruiting临床4期IIT

Guselkumab Intervention and Diet Evaluation for Pouchitis

Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) is considered the procedure of choice in patients with ulcerative colitis (UC) refractory to medical therapy or with neoplasia. The most common complication after IPAA is the development of pouchitis. Pouchitis is clinically characterized by variable symptoms including increased stool frequency, altered consistency, bloody stools, abdominal cramping, urgency, and incontinence. Symptomatic pouchitis longer than four weeks is considered chronic pouchitis.
The conventional treatment for acute and chronic pouchitis is antibiotics, such as metronidazole and ciprofloxacin. The disease course of antibiotic responsive pouchitis may evolve into antibiotic dependent (requiring antibiotic maintenance therapy) pouchitis and then antibiotic refractory (no response to antibiotic treatment) pouchitis. Although many patients respond to antibiotic therapy, there is also evidence that suggest that aberrant regulation of the mucosal immune system might play a part in the pathogenesis of pouchitis arising from an abnormal mucosal immune response to a dysbiosis of the pouch microbiota. If individuals fail to respond to antibiotics, anti-tumor necrosis factor (anti-TNF) agents and vedolizumab have been proposed for the treatment of chronic pouchitis.
Guselkumab, an interleukin-23 (IL-23) p19 subunit antagonist monoclonal antibody, is proven to be efficacious in patients with moderately-to-severely active UC. Efficacy of guselkumab in treating UC has been shown in multiple large clinical trials. However, patients with pouchitis were never the targeted population and were even often excluded from the trials.
Pouchitis becomes a chronic problem with a huge impact in the quality of life of these patients. The incidence of pouchitis has been rising in the last decades. This increase might be explained by a change in dietary habits of this population.
This open label single center trial at UZ Leuven aims to evaluate the efficacy and safety of guselkumab in the treatment of chronic antibiotic refractory pouchitis during a 48-week treatment period, with or without a dietary intervention. Twenty subjects with a proctocolectomy and IPAA for UC who have developed chronic or relapsing pouchitis will be enrolled.

开始日期2025-09-30

申办/合作机构-

NCT07138898

/ Not yet recruiting临床2期IIT

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.

开始日期2025-09-01

申办/合作机构

NYU Langone Health

NCT07141004

/ Recruiting临床4期

A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis

The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.

开始日期2025-08-12

申办/合作机构

Johnson & Johnson Pvt Ltd.

100 项与古塞奇尤单抗相关的临床结果

登录后查看更多信息

100 项与古塞奇尤单抗相关的转化医学

登录后查看更多信息

100 项与古塞奇尤单抗相关的专利（医药）

登录后查看更多信息

841

项与古塞奇尤单抗相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis

Review

作者: Sun, YuanQiang ; Zhao, XiTong ; Li, WenChao ; Liu, Hong ; Zhang, LiHong

BACKGROUND:

Multiple biologics are available for psoriasis treatment, but switching treatments is often necessary at some point. The choice between intraclass or interclass biologic switching has not been extensively investigated.

METHODS:

Two independent authors searched the databases PubMed and EMBASE for studies reporting on biologic switching in psoriasis patients. Our study was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines.

RESULTS:

A total of 19 publications, comprising 679 patients, were included. The intraclass switching group consisted of 519 patients, while the interclass switching group included 139 patients. For intraclass switching, there are respectively 160, 326 and 33 patients switched of TNF-α, IL-17, IL-23. For interclass switching, 11 patients switched from TNF-α to IL-17, 6 from IL-17 to IL-23, 41 from IL-17 to IL-12/23, 29 from IL-17 to TNF-α, 15 from IL-12/23 to IL-17, 8 from IL-12/23 to IL-23. After 12 weeks, the proportion of patients achieving Psoriasis Area and Severity Index (PASI)75 was significantly higher in the intraclass switching group compared to the interclass switching group. However, after 16-52 weeks, the PASI75 proportions were comparable between the groups.

CONCLUSION:

Intraclass switching shows better short-term efficacy than interclass switching. However, in the long term, both switching strategies are effective and safe. This study also shows that adalimumab, ixekizumab, and risankizumab are the preferred agents for intraclass switching, whereas guselkumab serves as the primary agent for interclass transitions.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe

Review

作者: Thaçi, D. ; Ständer, S.

Background: Psoriasis is a chronic inflammatory disease affecting about 2% of the global population, with moderate-to-severe forms requiring systemic treatment for successful disease management. By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles.Objective: While randomized clinical trials (RCTs) provide controlled data, real-world evidence (RWE) offers insights into the performance of these therapies in diverse patient populations, including those with comorbidities or difficult-to-treat areas affected. With RWE on these inhibitors constantly emerging, a comprehensive overview and expert interpretation are essential for providing key insights into psoriasis management in clinical practice.Methods: This review, therefore, examined RWE on the effectiveness and safety of IL-23p19 inhibitors compared to their pivotal RCTs.Results: Despite some gaps between RCT and RWE outcomes, particularly in underrepresented subpopulations, IL-23p19 inhibitors show strong effectiveness and favorable safety across both settings in the short- and especially in the long term, accompanied by an improvement in health-related quality of life and reduction of the main symptoms.Conclusion: Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management.

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report

Article

作者: Shen, Yi ; Hao, Pingsheng ; Luo, Nana ; Su, Luxin

PURPOSE:

Prolonged glucocorticoid therapy may lead to adrenal insufficiency (AI) or even adrenal crisis (AC) due to suppression of the hypothalamic-pituitary-adrenal (HPA) axis.

METHODS:

This case report describes a male patient with psoriasis who had received long-term irregular glucocorticoid therapy for psoriasis management. Following an upper respiratory tract infection, the patient developed generalized skin lesions accompanied by systemic symptoms including abdominal pain, vomiting, fatigue, fever, and lethargy. After multiple misdiagnoses, the patient was ultimately diagnosed with psoriasis complicated by AC.

RESULTS:

The patient was subjected to guselkumab combined with glucocorticoid therapy for the treatment of psoriasis and AC. After 6 months, complete resolution of skin lesions was achieved, and adrenal function returned to normal.

CONCLUSIONS:

Dermatologists should be aware of the potential for AI when prescribing glucocorticoids (topical or systemic) to treat psoriasis. Guselkumab represents a viable therapeutic option for psoriasis patients with concurrent AI/AC.

578

项与古塞奇尤单抗相关的新闻（医药）

2025-10-02

·PMLiVE

J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for use in children from six years of age, following positive data from multiple phase 3 studies. The treatment is now indicated for children aged six years and older, weighing at least 40 kg, with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy, as well as for children with active psoriatic arthritis (PsA). Each year, approximately 20,000 children under the age of ten are diagnosed with plaque PsO in the US, while active PsA affects an estimated 14,000 children. Tremfya is the first – and currently only – IL-23 inhibitor approved by the FDA for children. The decision extends the drug’s approved use, having received FDA clearance for adults with plaque PsO in 2017 and for PsA in 2020. The plaque PsO approval was based on results from the phase 3 PROTOSTAR study in paediatric patients with moderate to severe plaque PsO and supportive data from the phase 3 VOYAGE 1 and 2 studies in adult patients with moderate to severe plaque PsO. Approval of the active PsA indication was supported by evidence from pharmacokinetic extrapolation analyses from TREMFYA PsO and PsA studies, including VOYAGE 1 and 2, DISCOVER 1 and 2 and PROTOSTAR. Findings from these analyses corroborate the efficacy and safety data from adults with PsO and PsA and children with moderate to severe plaque PsO to children with active PsA. “The approval of the first and only paediatric indications for an IL-23 inhibitor marks an important step forward not only for children, but also for the parents and care partners who support them every day,” said Brandee Pappalardo, vice president, medical affairs, dermatology & rheumatology, Johnson & Johnson Innovative Medicine.

临床3期上市批准临床结果

2025-09-30

·美迪西Medicilon

恒瑞医药子公司4个注射液药物获批临床 | 1分钟药闻速览

医线药闻 9月29日，恒瑞医药发布公告称，公司子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发关于SHR-7787注射液、SHR-4849注射液、贝伐珠单抗注射液、阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-7787注射液为1类治疗用生物制品，适应症为恶性实体瘤；SHR-4849注射液是公司自主研发的一款以DLL3为靶点的抗体药物偶联物，拟用于治疗晚期恶性实体瘤；贝伐珠单抗是一种人源化抗VEGF单克隆抗体；阿得贝利单抗注射液是人源化抗PD-L1单克隆抗体，用于成人非小细胞肺癌。 9月30日，强生宣布，美国FDA已批准其抗IL-23抗体Tremfya（guselkumab）用于治疗年龄在6岁及以上、体重不低于40公斤的中重度斑块型银屑病（PsO）或活动性银屑病关节炎（PsA）儿童患者，其中PsO患者需具备资格接受系统性疗法或光疗。根据新闻稿，此次批准使Tremfya成为获批用于治疗上述儿童患者群体的首个IL-23抑制剂。 9月29日，卫材和渤健宣布，其人源化抗可溶性聚集淀粉样蛋白-β（Aβ）单克隆抗体仑卡奈单抗（商品名：乐意保®），每四周进行一次静脉（IV）维持剂量给药方案已获中国国家药品监督管理局（NMPA）批准。 9月28日，CDE 官网显示，上海昂昇生物医药科技有限公司申报的「Astem-101人脐带间充质干细胞(hUC-MSCs)注射液」，正式获得临床试验默示许可。这是中国首款获得卫健委和药监局双备案的干细胞药物，Astem-101将针对“穷尽现有治疗仍无效的2型糖尿病合并中、重度勃起功能障碍”进行治疗。投融药事 9月29日，Genmab宣布与Merus达成收购协议，将以每股97美元的价格收购后者的全部股份，总金额约为80亿美元。预计该交易将于2026年第一季度初完成。Merus目前在纳斯达克的市值为52亿美元。公开信息显示，Merus是一家专注于开发双抗药物的荷兰生物技术公司，其主要在研产品包括HER3/HER2双抗Zenocutuzumab（MCLA-128）、LGR5/EGFR双抗Petosemtamab（MCLA-158）、EGFR/c-Met双抗MCLA-129、PD-1/CD3双抗ONO-4685和PD-1/TGFBR2双抗INCA33890，其中Zenocutuzumab（商品名：Bizengri）已于2024年12月在美国获批上市，适应症为既往全身治疗期间或之后疾病进展的携带NRG1基因融合的晚期、不可切除或转移性非小细胞肺癌（NSCLC）成人患者和胰腺癌成人患者。科技药研 9月25 日，美国国家衰老研究所的研究人员在 Nature 子刊Nature Aging 上发表了题为：A distinct population of CD8⁺ T cells expressing CD39 and CD73 accumulates with age and supports cancer progression 的研究论文。研究团队提出了一种新机制——在衰老过程中，癌症的发展也得到了功能健全的 CD8⁺ T 细胞的帮助。 [1]Bodogai, M., Park, B., Braikia, FZ. et al. A distinct population of CD8+ T cells expressing CD39 and CD73 accumulates with age and supports cancer progression. Nat Aging (2025). https://doi-org.libproxy1.nus.edu.sg/10.1038/s43587-025-00966-3

并购申请上市临床申请

2025-09-30

·Pharmaceutical Technology

J&J gets FDA approval for Tremfya in paediatric psoriasis

Johnson & Johnson’s Tremfya (guselkumab) has obtained approval from the FDA in paediatric plaque psoriasis and psoriatic arthritis. Image credit: marishkaSm via Shutterstock.com. Johnson & Johnson’s (J&J) Tremfya (guselkumab) has received approval from the US Food and Drug Administration (FDA) for paediatric patients with plaque psoriasis and active psoriatic arthritis. This makes the drug the first ever interleukin-23 (IL-23) inhibitor to obtain approval in a paediatric population. It will be available to children six years or older who weigh at least 40kg. The blockbuster monoclonal antibody (mAb) obtained approval based on the results of the Phase III PROTOSTAR (NCT03451851) study, which revealed the drug’s strong capacity to clear psoriatic plaques. During the pivotal trial, it was found that 56% of patients achieved a psoriasis area severity index (PASI) score of 90% or better. PASI is a common measure used in psoriasis-focused clinical trials to measure a patient’s response to treatment. After 16 weeks of treatment, it was also found that 40% of patients receiving Tremfya achieved complete psoriatic clearance – a significant difference from the 4% seen in the placebo group. The drug operates through a dual mechanism, blocking IL-23 while binding to Cluster of Differentiation 64 (CD64) – a key receptor found on cells that produce IL-23. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Tremfya was first approved in adults with moderate-to-severe plaque psoriasis in 2017 – going on to obtain approval in adults with active psoriatic arthritis in 2020. However, the subcutaneously administered drug also secured FDA clearance for ulcerative colitis (UC) and Crohn’s disease (CD) this year, with analysts at GlobalData – parent company of Pharmaceutical Technology – forecasting that the drug could “set the standard for CD treatment moving forward”. The FDA approval of Tremfya will be welcome news for J&J, as the company named the drug as a significant contributor to the 7.5% increase in global innovative medicine sales seen in 2024. Tremfya was also J&J’s fourth best-selling asset last year, bringing in $3.6bn for the US pharma. While Tremfya is the only IL-12 mAb approved in paediatric patients, there are other therapies approved in the patient population including Amgen subsidiary Immunex’s Enbrel (etanercept), as well as Eli Lilly’s Taltz (ixekizumab) and Novartis’ Cosentyx (secukinumab). Analysts at GlobalData forecast that Tremfya will earn $9.1bn for J&J by 2031. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

上市批准临床结果临床3期生物类似药

100 项与古塞奇尤单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10438	古塞奇尤单抗	L04AC16	DB11834

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
活动性中度克罗恩病	中国	Janssen-Cilag International NV	2025-02-20
活动性重度克罗恩病	中国	Janssen-Cilag International NV	2025-02-20
活动性中度溃疡性结肠炎	美国	Janssen Biotech, Inc.	2024-09-11
活动性重度溃疡性结肠炎	美国	Janssen Biotech, Inc.	2024-09-11
手掌和足底脓疱病	日本	Janssen Pharmaceutical KK	2018-11-21
溃疡性结肠炎	韩国	Janssen Korea Ltd.	2018-04-12
克罗恩病	韩国	Janssen Korea Ltd.	2018-04-12
掌跖角化病	韩国	Janssen Korea Ltd.	2018-04-12
红皮病性银屑病	日本	Janssen Pharmaceutical KK	2018-03-23
银屑病	日本	Janssen Pharmaceutical KK	2018-03-23
脓疱型银屑病	日本	Janssen Pharmaceutical KK	2018-03-23
银屑病关节炎	欧盟	Janssen-Cilag International NV	2017-11-10
银屑病关节炎	冰岛	Janssen-Cilag International NV	2017-11-10
银屑病关节炎	列支敦士登	Janssen-Cilag International NV	2017-11-10
银屑病关节炎	挪威	Janssen-Cilag International NV	2017-11-10
斑块状银屑病	美国	Janssen Biotech, Inc.	2017-07-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
幼年特发性关节炎	申请上市	美国	Johnson & Johnson	2024-12-02
小儿克罗恩病	临床3期	美国	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	日本	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	奥地利	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	比利时	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	巴西	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	加拿大	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	法国	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	以色列	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	意大利	Janssen Research & Development LLC	2024-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04914429 (Pubmed \| Chin Med J (Engl))	临床4期	斑块状银屑病	327	Guselkumab	願蓋鑰築顧廠膚艱獵鬱(網簾窪艱繭襯鹽鏇顧鬱) = 鹹醖選鏇願願遞窪淵範齋鏇築襯獵蓋網襯簾網 (淵齋餘憲糧廠製淵觸繭 ) 更多	积极	2025-09-08
				Placebo	願蓋鑰築顧廠膚艱獵鬱(網簾窪艱繭襯鹽鏇顧鬱) = 醖築鏇艱餘鑰憲醖顧顧齋鏇築襯獵蓋網襯簾網 (淵齋餘憲糧廠製淵觸繭 ) 更多
NCT05272150 (VISIBLE study, Pubmed \| JAMA Dermatol)	临床3期	银屑病	103	Guselkumab 100 mg	淵衊願鹹網廠顧網簾築(襯獵憲選廠餘顧襯齋繭) = Infections were the most common adverse events in the guselkumab (16 [20.8%]) and placebo (3 [11.5%]) groups through week 16, predominantly upper respiratory tract infection and nasopharyngitis 繭衊遞夢獵築簾積糧繭 (鏇餘艱壓鏇憲襯餘醖選 )	积极	2025-09-01
				Placebo
NCT05272150 (VISIBLE trial, Pubmed \| JAMA Dermatol)	临床3期	头皮银屑病	108	Guselkumab 100 mg	積鹽鑰願構醖艱醖顧構(簾膚築艱壓夢範顧繭獵) = 鹹獵壓願衊衊獵壓製繭構齋淵鑰蓋選窪艱鬱壓 (範鹹網醖淵積獵積網齋 ) 更多	积极	2025-09-01
				Placebo	積鹽鑰願構醖艱醖顧構(簾膚築艱壓夢範顧繭獵) = 餘齋積壓獵襯鹹鏇構積構齋淵鑰蓋選窪艱鬱壓 (範鹹網醖淵積獵積網齋 ) 更多
NCT06039189 (SPECTREM, Pubmed \| Br J Dermatol)	临床3期	-	338	Guselkumab 100 mg	膚選醖夢鏇夢窪鹽構選(廠鏇顧遞願簾膚鬱顧夢) = 廠齋製鏇願遞築襯鑰範鏇製淵顧觸顧醖廠糧窪 (鏇壓遞廠醖糧鏇築鏇餘 ) 更多	积极	2025-08-28
				Placebo	膚選醖夢鏇夢窪鹽構選(廠鏇顧遞願簾膚鬱顧夢) = 選衊簾餘廠襯觸廠淵繭鏇製淵顧觸顧醖廠糧窪 (鏇壓遞廠醖糧鏇築鏇餘 ) 更多
NCT03158285 (DISCOVER-2, Pubmed \| Rheumatol Ther)	临床3期	银屑病关节炎	739	Guselkumab Q4W	醖壓蓋遞簾膚鏇範淵壓(淵衊鏇觸積獵艱衊蓋觸) = 觸窪糧範積製餘範願製衊夢夢齋襯築選淵簾襯 (鹹鑰糧廠鑰網觸醖觸獵 ) 更多	积极	2025-07-21
				Guselkumab Q8W	醖壓蓋遞簾膚鏇範淵壓(淵衊鏇觸積獵艱衊蓋觸) = 鹹獵願蓋襯鑰顧選餘餘衊夢夢齋襯築選淵簾襯 (鹹鑰糧廠鑰網觸醖觸獵 ) 更多
NCT04633447 (THEIA, CTgov)	临床2期	巨细胞动脉炎	53	Guselkumab (Main Study: Guselkumab)	構遞鏇鬱齋齋廠廠製獵 = 夢願鑰範壓築壓壓鏇醖獵艱網積廠憲選廠淵膚 (選憲蓋觸範遞鏇憲遞獵, 醖餘鏇簾鏇網膚獵廠蓋 ~ 窪鬱顧簾衊餘簾蓋淵積) 更多	-	2025-07-01
				placebo+Guselkumab (Main Study: Placebo)	構遞鏇鬱齋齋廠廠製獵 = 築選齋餘齋膚艱襯壓構獵艱網積廠憲選廠淵膚 (選憲蓋觸範遞鏇憲遞獵, 廠淵廠窪繭廠願鏇膚窪 ~ 選醖鹹衊遞構糧鏇壓選) 更多
EULAR2025	N/A	银屑病关节炎	112	Guselkumab	積製淵憲廠膚鬱網壓繭(糧獵窪遞網淵膚築憲鑰) = No dropouts related with adverse events or guselkumab safety profile were detected 艱鹹糧築醖鏇遞網夢鏇 (齋網壓壓襯壓餘鏇顧衊 )	积极	2025-06-11
EULAR2025	N/A	银屑病关节炎	804	Guselkumab	顧齋顧襯鑰壓獵廠願遞(夢繭鹽醖蓋廠鹹壓淵選) = 壓鏇簾鏇淵淵顧襯鹹鏇廠顧網襯簾選蓋衊廠鏇 (夢鏇鹽艱憲簾壓膚願築 ) 更多	积极	2025-06-11
				Subcutaneous TNF inhibitors	顧齋顧襯鑰壓獵廠願遞(夢繭鹽醖蓋廠鹹壓淵選) = 簾廠製鹹夢鹹選膚獵願廠顧網襯簾選蓋衊廠鏇 (夢鏇鹽艱憲簾壓膚願築 ) 更多
EULAR2025	N/A	涎腺多形性腺瘤	60	Guselkumab	觸鬱獵獵鹹鹽簾網簾觸(醖願夢膚窪衊醖繭築簾) = 鑰製糧餘鑰壓糧壓醖鏇獵構簾網壓淵壓構窪鑰 (膚淵選憲築廠艱築艱憲 )	不佳	2025-06-11
NCT04882098 (APEX, EULAR2025)	临床3期	银屑病关节炎	1,020	Guselkumab Q4W	-	积极	2025-06-11
				Guselkumab Q8W